Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx “Tripartisan” Group Backing Away From $400 Bil. Cost

Executive Summary

Proposals for a Medicare prescription drug benefit should increase the level of beneficiary cost sharing to fit within the available financial resources, Senate Finance Committee health policy director Linda Fishman told an Alliance for Health Reform forum Dec. 19 in Washington, D.C

You may also be interested in...



Medicare Rx Benefit Cited As Top Priority By Incoming Senate Leader Frist

Adding a prescription drug benefit to Medicare will be one of incoming Senate Majority Leader Bill Frist's (R-Tenn.) top priorities in the 108th Congress

Medicare Rx Benefit Cited As Top Priority By Incoming Senate Leader Frist

Adding a prescription drug benefit to Medicare will be one of incoming Senate Majority Leader Bill Frist's (R-Tenn.) top priorities in the 108th Congress

Senate Change Puts Hatch, Gregg, Grassley In Line For Key Rx Committees

The transfer of control in the Senate puts Sen. Orrin Hatch (R-Utah) in position to have greater influence in guiding generic drug reform legislation

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel